Strand Therapeutics has raised $153 million in second-round financing that will be used to move its programmable mRNA ...

Pfizer raised its earnings outlook slightly when it reported second-quarter earnings on Aug. 5, 2025. Upcoming losses of ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

Pfizer PFE reported second-quarter 2025 adjusted earnings per share of 78 cents, which comprehensively beat the Zacks ...